CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
1.730
0.00 (0.00%)
Aug 20, 2025, 4:00 PM - Market open
CytoMed Therapeutics Employees
CytoMed Therapeutics had 43 employees as of December 31, 2024. The number of employees increased by 9 or 26.47% compared to the previous year.
Employees
43
Change (1Y)
9
Growth (1Y)
26.47%
Revenue / Employee
$8,578
Profits / Employee
-$42,885
Market Cap
19.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43 | 9 | 26.47% |
| Dec 31, 2023 | 34 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GDTC News
- 2 days ago - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program - GlobeNewsWire
- 4 weeks ago - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - GlobeNewsWire
- 4 months ago - CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates - GlobeNewsWire
- 7 months ago - CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders - GlobeNewsWire
- 8 months ago - Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga
- 1 year ago - Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewsWire
- 1 year ago - CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewsWire
- 1 year ago - CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - Accesswire